Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

1,796.5 +36

_________ _________ ________

Product sales

Year to December 31,

Product sales US prescription

2007 2006 growth growth

US$M US$M % %

______________ __________ ______________ ________

Specialty

Pharmaceuticals

ADHD

ADDERALL XR 1,030.9 863.6 +19 +3

VYVANSE 76.5 - N/A N/A

DAYTRANA 64.2 25.1 +156 +166

ADDERALL - 23.6 N/A N/A

GI

PENTASA 176.4 137.8 +28 +3

LIALDA/MEZAVANT 50.5 - N/A N/A

RENAL

FOSRENOL 102.2 44.8 +128 +5

DYNEPO 14.2 - N/A N/A

Other

therapeutic

areas

CALCICHEW 54.2 45.5 +19 N/A

CARBATROL 72.3 68.3 +6 -5

XAGRID 66.8 53.3 +25 N/A

REMINYL/REMINYL XL 31.2 21.5 +45 N/A

Other 105.1 111.0 -5

_____________ __________ ______________

1,844.5 1,394.5 +32

_____________ __________ ______________

Human Genetic

Therapies

REPLAGAL 143.9 117.7 +22 N/A

ELAPRASE 181.8 23.6 +670 N/A

_____________ __________ _____________

325.7 141.3 +131

_____________ __________ _____________

Total 2
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Four-dimensional (4-D) printing develops materials ... external stimuli such as changes in temperature. This ... effect in multiple industries.  In the near future, ... printing objects ranging from human organs to parts ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... 21, 2014 On Wednesday of last week ... use Redox Signaling molecules, became available for purchase in Australia ... "The way that RENU 28 works is, if you think ... of the rate of cellular renewal within your body. If ... of that rate of cellular renewal. What RENU 28 does ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... BioSciences Inc.,(AMEX: YMI , TSX: YM, AIM: ... differentiated products for patients worldwide,today announced that clinical ... nimotuzumab, a humanized monoclonal antibody that targets,the epidermal ... American,Society of Clinical Oncology (ASCO) Annual Meeting being ...
... MONTVALE, N.J., June 3 Contemporary ... dedicated to enhancing the surgeon,s,practice, has announced ... tool:,SURGERYFINDIT.COM ( http://www.SURGERYFINDIT.COM )., As part ... surgeons with a wealth of peer-reviewed, practical ...
... 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ... device company, today announced the completion of U.S. ... track plug., "Our proprietary Bio-Seal product represents ... diagnose lung cancer," said Dr.,William Hunter, President and ...
Cached Biology Technology:NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 2NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 3NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 4SURGERYFINDIT.COM and Convera(R) Launch Vertical Search Site for Surgeons 2Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 2Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 3Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 4
(Date:8/20/2014)... years, Virginia Tech,s Wu Feng has built upon a ... "Computing in the Cloud" program, and synergistically complemented it ... from the Air Force on "big computing" for mini-drones ... National Institutes of Health on "big data" for the ... computing" aspects from each grant, he was able to ...
(Date:8/20/2014)... of honeybees grows to about 4,000 members, it triggers ... building of a special type of comb used for ... from the Department of Neurobiology and Behaviour at Cornell ... reproductive cycle of honeybee colonies. The results are published ... Nature . , Reproduction isn,t always a honeybee ...
(Date:8/20/2014)...  The second annual Biometrics UnPlugged Executive Summit, ... Florida on September 15, 2014, will ... and Strategy at Samsung, and Philippe de Raet, Vice ... this year,s event is Mobility at the Crossroads ... UnPlugged: Mobility at the Crossroads of Commerce & ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... created a synthetic protein that, when activated by ultraviolet light, ... arthritis and other serious medical disorders can be detected. ... imaging technology and may someday serve as a way to ... disease have been found. In a study published in the ...
... be changed by a restaurant,s choice of music and lighting, ... a new study., "When we did a makeover of a ... diners to eat 175 fewer calories and enjoy it more," ... and director of Cornell University,s Food and Brand Lab. ...
... Conn., Aug. 29, 2012 /PRNewswire-iReach/ -- The biobanking market presents ... drug and treatment development for specific diseases. The global ... is projected to increase by 30% between 2010 and 2015, ... sector biobanks will experience the greatest increase with growth of ...
Cached Biology News:Collagen-seeking synthetic protein could lead doctors to tumor locations 2Collagen-seeking synthetic protein could lead doctors to tumor locations 3Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 2Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 3
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... to Asparagine synthetase ( Abpromise ... Antigen: ... in the C-terminus of Human ... Entrez GeneID: 440 ...
Biology Products: